-
Mashup Score: 86Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma - 15 day(s) ago
Bone Marrow Transplantation – Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 116Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy - 22 day(s) ago
Blood Cancer Journal – Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
🎉Finally out and timely for #ASH24 @ASH_hematology🎉 Happy to share our international work suggesting bispecific antibodies as standard of care for relapse after CAR-T in multiple #myeloma #mmsm @BloodCancerJnl https://t.co/F7QjOoavKO
-
-
Mashup Score: 68
There is insufficient evidence to support routine use of tranexamic acid to reduce bleeding in patients with haematological malignancies undergoing intensive chemotherapy.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
Prophylactic tranexamic acid does not benefit patients with hematological malignancies and thrombocytopenia. Important study with hypothesis generation for study designs and clinical scenarios now out @TheLancetHaem Congrats to the whole team! https://t.co/Squ44Q4wwD https://t.co/OE0VUNSWBH
-
-
Mashup Score: 13
Program: Oral and Poster Abstracts Type: Oral Session: 655. Multiple Myeloma: Cellular Therapies: Unleashing Cell Therapies Against Myeloma Hematology Disease Topics & Pathways: Research, Clinical trials, Clinical Research 1 Department of Hematology, General Hospital of the Chinese People’s Liberation Army Western Theater, Chengdu, Sichuan, China 2 Branch of National Clinical Research Center for Hematological Disease, Chengdu, Sichuan, China 3 Sichuan Clinical Research Center for Hematological Disease,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Phase I trial of anti-BCMA/GPRC5D bispecific CAR T-cells in extramedullary disease: -Efficacy: 100% ORR; 50% CR -Safety: CRS in 62.5% (all mild/moderate). Promising for RRMM with EMD, further studies needed to confirm and optimize. #ASH24 https://t.co/d9UcEr8IxQ
-
-
Mashup Score: 5
Program: Oral and Poster Abstracts Type: Oral Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: JAK Inhibitors in MPDs, Novel Insights and Next-Gen Agents Hematology Disease Topics & Pathways: Apoptosis, Clinical trials, MPN John O. Mascarenhas, MD 1, Prithviraj Bose, MD 2, Hsin-An Hou, MD, PhD, MSc 3 *, Wojciech Homenda, MD, PhD 4 *, David Ross, MD 5 *, Sanjay R Mohan, MD, MSc 6, Jean-Jacques Kiladjian, MD, PhD 7, Haifa Kathrin Al-Ali, MD; PhD 8 *, Andrew Charles Perkins, MBBS,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Navtemadlin for JAK inhibitor refractory myelofibrosis (BOREAS): 👉reduced CD34+ counts by -82% at Week 24 👉47% of Navtemadlin-treated patients improved fibrosis grade at Week 24 👉≥50% reductions in driver mutations in 18% #ASH24 https://t.co/FgS01XTYax
-
-
Mashup Score: 11
Program: Oral and Poster Abstracts Session: 655. Multiple Myeloma: Cellular Therapies: Poster I Hematology Disease Topics & Pathways: Research, Clinical Research, Plasma Cell Disorders, Diseases, Real-world evidence, Lymphoid Malignancies Nico Gagelmann, MD 1 *, Friedrich Stölzel 2 *, Roland Fenk, MD, PhD 3 *, Tobias A.W. Holderried, MD 4 *, Fabian Mueller, MD 5 *, Natalia Tovar, MD 6 *, Aina Oliver-Caldés, MD, PhD 7 *, Kristin Rathje 8 *, Vladan Vucinic, MD 9 *, Soraya Kharboutli, MD 5 *, Ben-Niklas
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Cilta-cel superior and with distinct cellular dynamics (Europe): -Cilta-cel with better ORR, CR, PFS -Similar NRM -Peak CAR-T expansion day 14 for cilta-cel and day 7 for ide-cel -Expansion associated with response for both and ICANS for cilta-cel #ASH24 https://t.co/CHu4vZYEZz
-
-
Mashup Score: 13
Program: Oral and Poster Abstracts Type: Oral Session: 655. Multiple Myeloma: Cellular Therapies: Unleashing Cell Therapies Against Myeloma Hematology Disease Topics & Pathways: Research, Clinical trials, Clinical Research 1 Department of Hematology, General Hospital of the Chinese People’s Liberation Army Western Theater, Chengdu, Sichuan, China 2 Branch of National Clinical Research Center for Hematological Disease, Chengdu, Sichuan, China 3 Sichuan Clinical Research Center for Hematological Disease,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Phase I trial of anti-BCMA/GPRC5D bispecific CAR T-cells in extramedullary disease: -Efficacy: 100% ORR; 50% CR -Safety: CRS in 62.5% (all mild/moderate). Promising for RRMM with EMD, further studies needed to confirm and optimize. #ASH24 https://t.co/d9UcEr8IxQ
-
-
Mashup Score: 11
Program: Oral and Poster Abstracts Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III Hematology Disease Topics & Pathways: Research, Clinical trials, Clinical Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies Michael R Bishop, MD 1, Jacalyn Rosenblatt, MD 2, Binod Dhakal, MBBS 3, Noopur Raje 4, Daniella Cook, BS 5 *, Mahmoud R. Gaballa, MD 6, Estelle
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Anito-cel for RRMM: -Efficacy: 95% ORR, 62% CR/sCR; 92% MRD negativity (10⁻⁵) -Safety: 84% CRS (mostly mild); 9% ICANS (all resolved); no delayed neurotoxicity -Survival: 6-month PFS 90%, OS 95% Promising deep and durable responses. #ASH24 https://t.co/X1QpnOn7Yc
-
-
Mashup Score: 80Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis - 1 month(s) ago
Key Points. MIPSS70 high patients benefit from transplantationMIPSS70 intermediate patient may benefit from transplantation if their MTSS score is low or i
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
🎉Finally out🎉 Role of molecular alterations in transplant decision for primary myelofibrosis Wonderful international collaboration @jjkiladjian @CarmeloGurnari @chr_reinhardt @fredhutch @BartScott8 #mpnsm https://t.co/EMgGPYEOIo
-
-
Mashup Score: 15Contest Session - 1 month(s) ago
The EBMT is pleased to offer the second edition of the EBMT Contest to actively promote dialogue and information exchange on more philosophical topics related to HCT and Cellular Therapy.The five best essays will be selected and presented in-person at the 51st Annual Meeting of the EBMT in Florence on 30 March – 2 April 2025.
Source: www.ebmt.orgCategories: General Medicine News, Hem/OncsTweet-
Submit your essay for Contest Session at @TheEBMT Annual Meeting in Florence🇮🇹 on Machine Dreams: How can AI shape hematology now and in the future Trainees, nurses, physicians, psychologists, pharma, show your vision! @TheEBMT_Trainee https://t.co/qBGPdJozz8
-
🎉Finally out🎉 Tandem transplant should be reserved to myeloma patients with sub-optimal responses to induction therapy AND a first transplant Congrats Max Merz and team @BMTjournal #mmsm https://t.co/uuVb1taUDh